Germany · Delayed Price · Currency is EUR Poxel Company Description
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases.
The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan.
It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications.
The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin.
Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
| Country | France |
| Founded | 2009 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 6 |
| CEO | Nicolas Trouche |
Contact Details
Address: Immeuble Le Sunway Lyon, Auvergne 69007 France | |
| Phone | 33 1 44 71 94 94 |
| Website | poxelpharma.com |
Stock Details
| Ticker Symbol | 7PO |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nicolas Trouche | Chief Executive Officer |
| Fanny Bosa | Chief Financial Officer |
| Arthur Rouille | Head of Investor Relations |